Fruquintinib
- Generic Name
- Fruquintinib
- Brand Names
- Fruzaqla
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O5
- CAS Number
- 1194506-26-7
- Unique Ingredient Identifier
- 49DXG3M5ZW
- Background
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
- Indication
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Dai, Guanghai
- Target Recruit Count
- 46
- Registration Number
- NCT06685276
- Locations
- 🇨🇳
China PLAGH, Beijing, China
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT06646588
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Ningbo Medical Center Lihuili Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06613113
- Locations
- 🇨🇳
Kaitai Liu, Ningbo, Zhejiang, China
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 78
- Registration Number
- NCT06562543
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Liu Huang
- Target Recruit Count
- 80
- Registration Number
- NCT06551207
- Locations
- 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 68
- Registration Number
- NCT06543836
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 430
- Registration Number
- NCT06497985
- Locations
- 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Phase 1
Not yet recruiting
- Conditions
- To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal CarcinomaTo Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal CancerCombination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 25
- Registration Number
- NCT06484153
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT06446154
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 84
- Registration Number
- NCT06441565
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath